Introduction

Essential tremor (ET) is the most common movement disorder, with a prevalence of more than 60 million individuals worldwide1. ET is mainly characterized by an action tremor of the upper limbs, possibly with the involvement of other parts of body, like the head, voice and lower limbs2. The clinical profile of ET represented not only with motor symptoms, but also with some non-motor features, including gastrointestinal disorders3.

Recently, the crucial role of gut microbiome has been suggested in the pathogenesis of neurodegenerative diseases, such as Parkinson’s disease (PD)4, Alzheimer’s disease (AD)5, and multiple system atrophy (MSA)6. The gut microbiome consists of a large complex community of microbes that colonize the gastrointestinal tract. The brain-gut-microbiome axis not only allows the brain to control gut function but also provides an opportunity for the gut microbiome to influence the brain7. An interesting case report of ET showed the symptom improvement after fecal microbiota transplantation8, indicating the relationship between gut microbiome and ET. However, the specific microbial alterations of ET have not yet been investigated.

As for gut dysbiosis in neurodegenerative diseases, PD is the most widely studied9. The imbalanced microbiome enhanced intestinal permeability and activated the enteric glial cells, which contributed to alpha-synulceinopathy10. PD shares certain overlapping features with ET11, making it challenging to distinguish one from the other, especially for pseudo-bradykinesia12 and sorely action tremor in early-stage PD13. On the other hand, some ET patients may develop to PD with the disease progression14, making it urgent for us to study the difference between ET and PD in gut dysbiosis.

Thus, our study aimed to find specific gut microbiota alterations in ET and its difference from PD. Previous studies indicated that anti-PD medications, such as catechol-O-methyltransferase (COMT) inhibitors, amantadine and monoamine oxidase B (MAO-B) inhibitors, might interfere with the results of microbiotal alterations analysis15,16,17. Changes of genera Dorea and Phascolarctobacterium in PD were dose-dependent with levodopa medications18. To eliminate the confounding factor of anti-PD medication, we select de novo PD patients as disease control to analyze the gut microbial difference between ET and PD. In addition, since the traditional 16S rRNA sequencing has the shortage of misinterpreting microbial community structures19, we adopted quantitative PCR (qPCR) with 16S rRNA gene sequencing data to obtain the accurate estimation of absolute abundance. Moreover, we also included enterotype analysis to see the difference between groups. Finally, we recruited three groups of ET, PD and matched normal controls (NC) to find out the specific gut microbiota changes in ET.

Results

Demographics and clinical characteristics of subjects

The demographics and clinical characteristics of ET, NC, and PD were summarized in Table 1. Ten out of the 54 ET patients were treated with beta-blocker (9 with arotinolol and 1 with propranolol) while 3 PD patients and 1 NC took beta-blocker for cardiac concerns. There were no significant difference in age, gender, BMI, MMSE, diabetes, as well as daily habits of smoke, alcohol, tea, coffee among three groups (P ≥ 0.085). In addition, ET patients had longer disease duration (P < 0.001) and lower SCOPA-AUT total score (P = 0.014) compared to PD patients. As for emotion, ET patients exhibited significant higher score in HAMD-17 (P < 0.001), and HAMA (P < 0.001) compared with NC, but no significant difference was found in HAMD-17 (P = 0.297) or HAMA (P = 0.840) compared with PD.

Table 1 General characteristics of the study subjects.

16S rRNA sequencing and qPCR results overview

In total, 8,184,232 high-quality 16S rRNA gene V3–V4 sequences were obtained, with 40182 per sample after demultiplexing and quality control. A total of 19 phyla, 27 classes, 49 orders, 80 families, 225 genera, and 321 species were identified. The dominant genera were Bacteroides (18.8%), Prevotella (5.1%), Ruminococcus (3.5%), Faecalibacterium (3.3%) in relative abundance data, and Bacteroides (2.8 × 109), Prevotella (7.4 × 108), Faecalibacterium (3.3 × 108) and Subdoligranulum (2.6 × 108) in absolute abundance data (Supplementary Fig. 1).

Microbiota diversity and enterotype distribution among ET, NC and PD

For alpha-diversity, Chao1 index was significantly different among ET, NC and PD groups (Fig. 1a, P = 0.005) and Chao1 index of ET patients was lower than that of NC (P = 0.047) and PD patients (P = 0.001). The significant difference of Chao1 index retained after ridge regression analysis adjusted for the significantly different clinical characteristics (HAMD-17, HAMA, Bristol and Wexner, P = 0.016). No significant difference was found in Shannon or Simpson indices among these groups (Fig. 1b, c, P = 0.560, P = 0.633 respectively).

Fig. 1: Differences in alpha diversity, beta diversity, and the composition and distribution of enterotype summarized among three groups comparison.
figure 1

ac Box plots showing the between-group comparisons of the alpha diversity of gut microbiota by Chao, Simpson, and Shannon index. d Beta diversity visualized by PCoA. e All fecal samples were clustered into 3 enterotypes. f Every color represented the dominant component of each enterotype as light blue standed for Bacteroides-dominant enterotype, green standed for Prevotella-dominant enterotype and dark blue standed for Ruminococcus-dominant enterotype. g Three-type enterotype distribution in ET, NC, and PD.

Additionally, beta-diversity (Weighted Unifrac) was found to be remarkably different among three groups (Fig. 1d) (ANOSIM R2 = 0.021, P = 0.034), especially between ET and PD patients (ANOSIM R2 = 0.045, P = 0.012). However, there is no significant difference between ET and NC (ANOSIM R2 < 0.001, P = 0.868). To determine whether this significance was driven by these four significantly different clinical characteristics (HAMD-17, HAMA, Bristol, and Wexner), PERMANOVA with adjustments showed that the significance of group status retained (P = 0.003) and explained 3.4% of the total variation in the microbiome, while Bristol also showed significance (P = 0.003) with 2.6% of the total variation.

We next investigated the microbial enterotype features by dividing into 3 clusters (Fig. 1e). Enterotype 1 was dominated by Bacteroides as the most enriched genus and Prevotella was core in enterotype 2, while Ruminoccocus was the predominance in enterotype 3 (Fig. 1f). Significant distribution difference was observed among three groups (P < 0.001, Fisher’s test). Difference between ET patients and NC was not significant (P = 0.850, Fisher’s test), while comparison between ET and PD showed statistical difference (P < 0.001, Fisher’s test).

Specific fecal microbiota changes in ET compared to NC and PD

LEfSE analysis showed key taxa for distinguishing ET patients from NC. Considering the consistent results of relative and absolute data at genus level, ET patients had lower abundances of 7 genera (Ruminococcus, Romboutsia, Mucispirillum, Aeromonas, Helicobacter, Candidatus Arthromitus and Peptoclostridium) compared to NC (Fig. 2). These genera remained significance after ridge regression adjusted for the statistically different clinical features between ET and NC (HAMD-17 and HAMA). ROC curve from the 4 most distinctive genera (Ruminococcus, Romboutsia, Mucispirillum, and Aeromonas) selected from their combined relative and absolute abundance data was with an AUC of 0.705 (95%CI 0.608–0.802, sensitivity 64.8% and specificity 64.8%, P < 0.001). (Supplementary Fig. 2a)

Fig. 2: Significant gut microbiota differences between ET and NC in both relative and absolute taxon at genus level.
figure 2

Taxa listed according to their LDA values (superior to 2.0) determined from comparisons between ET and NC groups and only the consistent significant taxa from both relative and absolute data were extracted. LDA linear discriminant analysis.

In particular, only the genus Peptoclostridium was found distinctly lower in ET patients whenever compared with NC or PD. Moreover, the abundance of other 17 genera (Holdemanella, Eggerthella, Catenibacterium, Fastidiosipila, Senegalimassilia, Chryseobacterium, Bacillus, Cellulosimicrobium, Anaerococcus, Mogibacterium, Herbaspirillum, Gordonibacter, Shuttleworthia, Paenibacillus, Paracoccus, Parascardovia, Anaerofustis) in ET patients was lower than those in PD patients, whereas 8 genera (Bacteroides, Fusobacterium, Phascolarctobacterium, Lachnospira, Lachnoclostridium, Bilophila, Sutterella, Rikenella) were higher than those in PD patients (Supplementary Fig. 3). Among them, Cellulosimicrobium was the only genus affected by Wexner (relative, P = 0.040; absolute, P = 0.033) in both relative and absolute abundance after ridge regression analysis adjusted for the statistically significant confounding factors (Bristol, Wexner, disease duration and SCOPA-AUT). ROC curve from the 4 most distinctive genera (Bacteroides, Fusobacterium, Phascolarctobacterium and Lachnospira) selected from their combined relative and absolute abundance data for the differentiation between ET and PD was with an AUC of 0.756 (95%CI 0.672–0.841, sensitivity 68.6% and specificity 74.0%, P < 0.001) (Supplementary Fig. 2b). Besides, in the comparison between PD and NC, the abundance of other 17 genera in PD patients was lower than those in NC, whereas 13 genera were higher in NC than those in PD patients, which was displayed in detail in Supplementary Fig. 4.

Functional Prediction of fecal microbiota in ET

PICRUSt2 was applied to predict the changes of functional gene composition of fecal microbiota in the samples at KEGG database. There was no statistical difference between ET and NC at level 1 or level 2. At level 3, ET microbiota were enriched for pathways related to renin secretion, mannose type-O-glycan biosynthesis and other types of O-glycan biosynthesis than those of NC, while NC microbiota were enriched for parathyroid hormone synthesis, secretion, and action pathway (Fig. 3). Differences in many functional pathways between ET and PD patients were found. Compared with PD, a total of 68 metabolic pathways (KEGG level 3) were found to be significantly different (P < 0.05), including those involved in metabolism of glycan biosynthesis, vitamins, and amino acids, as well as signaling, transport and catabolism. These results were detailed in Supplementary Fig. 5. All these significantly different pathways survived after FDR correction, regardless of the comparison between ET and NC or between ET and PD (Supplementary Tables 1, 2).

Fig. 3: Significant KEGG pathways at level 3 in both relative and absolute data for the fecal microbiome of ET and NC visualized by STAMP.
figure 3

*P < 0.05, **P < 0.01, ***P <0.001.

Association between fecal microbiota and clinical features in ET

The associations between fecal microbiota at genus level and clinical features were shown in Supplementary Fig. 6. With the combination of both relative and absolute abundance data of ET, 62 significant paired genus-clinical characteristic correlations were found. (Supplementary Fig. 6). After ridge regression analysis adjusted for confounding factors, 5 significant associations remained: Klebsiella had significantly positive correlation with HAMD-17 and HAMD, Proteus was positively correlated to HAMD-17 and TETRAS, Anaerococcus was negatively linked to MMSE both in relative and absolute abundance data (Table 2 and Supplementary Fig. 7). Besides, when focusing on the 7 distinctive genera between ET and NC identified in LEfSE analysis, we found that Romboutsia had significantly positive correlation with Bristol (r = 0.30 and P = 0.025 in relative abundance, r = 0.28 and P = 0.038 in absolute abundance), and Helicobacter had significantly negative correlation with SCOPA-AUT (r = −0.35 and P = 0.010 in both relative and absolute abundance). But these above associations did not remain after ridge regression analysis adjusted for confounding factors.

Table 2 Spearman’s correlation for fecal microbiota at genus level and clinical features.

Discussion

Our study analyzed the fecal microbiota alterations in ET and its difference from PD. De novo PD patients were chosen for disease control to exclude the confounding effect of anti-PD medication. To note, 10 of 54 ET patients took beta-blocker as treatment, which was reported to have almost little association with gut microbiota20. Therefore, we did not include beta-blocker into the confounding factor for adjustment. Besides, our study also introduced absolute quantification analysis of fecal microbiome except for relative quantification analysis. Finally, the specific gut microbiota changes in ET were performed with functional prediction and clinical association analysis for deep insight into the clinical significance of the findings.

For the bacterial community, our results of alpha diversity indicated that the species richness (Chao1 index) was statistically different in ET patients compared with NC and PD. Beta diversity of Weighted Unifrac distance metrics with adjustments indicated significant difference in three groups’ comparison and the associated clinical feature (Bristol) might affect the gut microbiome. In particular, the enterotype profiling results between the three groups showed significant difference. Enterotype profiling refers to the stratification of human gut microbiota and is regarded as a reliable method to understand the microbiota community irrespective of age, gender, and ethnicity21. In our study, we adopted the classical three-enterotype model22 and found that the ET was mostly Bacteroides-dominant, similar to the distribution of NC. Whereas PD was with a tendency towards the enterotype dominated by Ruminococcus. Ruminococcus-dominant enterotype was reported to have the lowest overall bacterial growth rate23, possibly indicating the fragility to protect the equilibrium of intestinal barrier and the aggravation of intestinal inflammation in PD pathogenesis. Although the enterotype itself might not be sufficiently useful for differentiating ET and PD, it may still be relevant in various clinical settings, including potential disease association24.

Regardless of the similarity of enterotype distribution between ET and NC, there still existed taxonomic differences. At genus level, there were reduced abundances of 7 genera in ET patients than those in NC, including Ruminococcus, Romboutsia, Mucispirillum, Aeromonas, Helicobacter, Candidatus Arthromitus, and Peptoclostridium, not influenced by differential clinical characteristics. Romboutsia and Ruminococcus are both fermenting anaerobes that lead to the production of short-chain fatty acids (SCFAs)25,26. SCFAs are the provital part to maintain the stability of colonic mucosa and fight against intestinal inflammation27. In addition, Candidatus Arthromitus was proved to be protective for healthy gut and could help fighting against pathogens resulting in morbidity and decreased performance in turkey model28. The decrease of these beneficial genera may participate in the immune response of opportunistic pathogens and the modulation of intestinal permeability. Besides, Helicobacter29, Peptoclostridium30 and Aeromonas31 were considered multifactorial and could lead to the immune host response in certain virulent circumstances. Although we couldn’t clarify the precise role of the altered gut microbiota in ET due to its limitation to species level interpretation, we still confirmed its specific taxa difference and this published literature of such microbial function could give hints for further research.

The gut microbiota changes in ET compared with PD provided the first evidence of the difference in gut dysbiosis of ET from PD. Of which, some taxa were reported in the previous studies of PD gut dysbiosis compared with NC, such as increased Eggerthella26 and Peptoclostridum32, decreased Bacteroides33 in PD patients and these aforementioned alterations were the same as in the comparison between PD and NC in our study. This finding indicated that some taxa alterations might be specific for PD. Besides, the comparison between PD and NC based on de novo cases and quantitative approach provided more robust evidences for the gut dysbiosis in PD without the interference of anti-PD medication. In addition to the 3 genus (increased Eggerthella26 and Peptoclostridum32, and decreased Bacteroides33) mentioned above, increased Catabacter34 and decreased Faecalibacterium34 presented the same trend with previous study while the other novel findings (like increased Holdemanella, increased Chryseobacterium,etc) needed larger numbers of de novo subjects with the same approach to be confirmed.

Based on the results of between-group comparisons, 4 genera (Ruminococcus, Romboutsia, Mucispirillum, and Aeromonas) were selected for the distinction of ET from NC with an AUC of 0.705. For differential diagnosis between ET and PD, 4 genera (Bacteroides, Fusobacterium, Phascolarctobacterium, and Lachnospira) were found remarkable with an AUC of 0.756. Overall, specific gut microbiota alterations might be a useful indicator to differentiate ET from NC and PD. Further investigation for a broader analysis of microbial composition seemed to be worthwhile.

The comparison of functional prediction between ET and NC indicated 4 altered metabolic pathways according to the KEGG hierarchical level 3 classification, which could give insights to the following research on the interaction between gut dysbiosis and the host. Further study using metagenomic sequencing and metabolites analysis to study the functional alterations of microbes in ET is crucial.

Correlation analysis of specific taxa and clinical symptoms found a positive correlation between Proteus and TETRAS. Although no previous study has directly mentioned the association between ET severity and microbiota, an animal study has shown the administration of one specie of Proteus (Proteus mirabilis) could induce motor deficits via gut leakage and brain inflammation35. On the other hand, Klebsiella was found positively related to emotional change in ET, such as anxiety and depression. Previous researches have also confirmed that an increase of Klebsiella was associated with major depressive disorder36 and could induced anxiety in mice model37. In all, these previous studies were consistent with the correlation between gut microbiota and clinical features in our study. Thus, despite that functional studies of gut microbiota need to focus on specie level instead of genus level, our results could still give limited clues for further study.

There are still several limitations in our research. Firstly, given the cross-sectional nature of our study, the observational results cannot prove cause and effect association. Secondly, dietary patterns and food preferences may impact the microbiota expression, a larger-scale research samples from different populations are warranted, and a complete and systematic dietary interrogation, like EPIC-Norfolk Food Frequency Questionnaire38, should be added in the future study.

In conclusion, this study provides preliminary data revealing gut dysbiosis in ET, and identify the relation between gut microbiota and clinical features. It also provides new insight into the pathogenesis of ET and help distinguishing ET from PD.

Methods

Study subjects

One hundred and seventy-five subjects (54 ET, 67 PD, and 54 NC) from outpatient clinic of Movement disorders Center in Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine were enrolled in our study between January 2018 and August 2021. This study was approved by the Institutional Review Board of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Written informed consents were obtained from all of the participants. Inclusion criteria were: (1) aged 25–85 years, (2) ET patients were diagnosed according to MDS Task Force criteria2 and PD diagnosis was based on MDS criteria39 for PD patients, (3) no anti-PD medication intake before the fecal sample collection of all subjects, (4) solely beta-blocker intake or no relevant medication intake before the fecal sample collection for ET group. NC matched by age, gender, and body mass index (BMI) were selected simultaneously. Exclusion criteria were: (1) vegetarian or malnutrition, (2) chronic gastrointestinal disorder (including inflammatory bowel disease, gastric or duodenal ulcer), (3) severe chronic illness (including malignant tumor, heart failure, renal insufficiency, hematological disorder, etc), (4) history of major gastrointestinal surgery, (5) ongoing or regular consummation of yogurt, (6) no use of any probiotic or antibiotic within one month, (7) ongoing use of corticosteroid, proton pump inhibitor, statin, Metformin, immunosuppressant or anti-neoplastic medication, (8) severe cognitive deficit that obstructed the execution of clinical assessment.

Clinical evaluation

All subjects provided information of medical history, weight, and height for the calculation of BMI, and accepted neurological examination and clinical assessment, such as Hamilton Anxiety Scale (HAMA) for anxiety40, Hamilton Depression Scale-17 items (HAMD-17) for depression41, Wexner constipation score and Bristol stool scale for constipation severity42,43, Mini Mental State Examination (MMSE) for cognition44. The Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT) was interrogated for ET and PD patients for autonomic dysfunction45. Fahn-Tolosa-Marin Clinical Rating Scale for Tremor (FTM)46 and the Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS)47 were examined among ET patients; the Movement Disorder Society sponsored version of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)48 and the Hoehn and Yahr stage (H-Y stage)49 were examined for PD patients, respectively.

Fecal sample collection and sequencing

In accordance with our previous study6, each participant was asked to collect a fecal sample in the morning using fecal collection containers. The containers were transferred on ice and stored at −80 °C prior to processing. The DNA was extracted from 200 mg samples using the QIAamp ® Fast DNA Stool Mini Kit (QIAGEN, Hilden, Germany) following the manufacturer’s instructions. Microbial composition was determined by 16S rRNA gene sequencing of DNA extracted from stool by amplifying the V3–V4 regions. DNA was checked by running the samples on 1.2% agarose gels. Polymerase chain reaction (PCR) amplification of 16S rRNA genes was performed using general bacterial primers (357F and 806R) with two-step amplicon library building on the Novaseq platform.

At the same time, we calculated the total bacteria load with 3 replicates by using quantitative real-time PCR. The PCR product of the target microbiota gene was used as a standard control, followed by amplification using the TaKaRa® SYBR PremixTaq kit according to the manufacturers’ instructions. PCR amplification was performed using the same general primers (357F and 806R). The reaction conditions were as follows: pre-denaturation at 95 °C for 30 s, denaturation at 95 °C for 10 s, annealing at 55 °C for 30 s, extension at 72 °C for 30 s (40 cycles), and final extension at 72 °C. Standard curves were set up by serially diluting plasmid of a pMD18-T vector with the appropriate insert from 107 to 1012 target gene copies µl−1 for each primer set. The details were described in Supplementary Information.

Statistical analysis

The 16S sequences were analyzed by using a combination of software Trimmomatic50 (version 0.35), Flash51 (version 1.2.11), UPARSE52 (version v8.1.1756), mothur53 (version 1.33.3) and R54 (version 3.6.3). The raw 16s rRNA gene data were processed to form operational taxonomic units (OTUs) at 97% identity using UPARSE. Taxonomy was assigned using Silva 128 as the reference database. The relative abundances obtained from 16S rRNA sequencing were quantified to get absolute abundance (copies/gram) by multiplying the total bacterial load performed by qPCR.

The characteristics of all subjects were compared by Kruskal–Wallis/Wilcoxon rank-sum test and chi-squared test/Fisher’s exact test.

Alpha and beta diversity were analyzed based on the absolute abundance. Alpha diversity analysis was performed using Chao1 index for species richness, Shannon and Simpson indices for species diversity. The ridge regression analysis was then performed by adjusted for the significantly different clinical characteristics among groups to avoid the confounding factors. Beta diversity analysis between groups was visualized by principal coordinate analysis (PCoA) and calculated by ANOSIM with weighted Unifrac analysis55. To control confounding factors, we conducted permutational multivariate analysis of variance (PERMANOVA)56 with groups and used those significantly different characteristics as covariates, and the fraction of the total variance explained by each variable was calculated in this model. Meanwhile, enterotype features were examined by dividing into 3 clusters by principal coordinate analysis based on the Jensen-Shannon divergence22.

The genus level was selected for further analysis and the following analysis were based on the consistent results of relative and absolute abundance data. Linear discriminant analysis (LDA) Effect Size (LEfSE) analysis57 was used for between-group comparisons with an alpha cutoff of 0.05 and an effect size cutoff of 2.0. Also, ridge regression analysis was conducted for controlling the confounding factors. The 4 most discriminant genera were identified by LEfSE analysis between groups with the highest LDA scores extracted from the consistent results (overlapped genera) of relative and absolute data. Subsequently, the data of relative abundance, absolute abundance, and the combination of relative and absolute abundance of the four most discriminant genera were put into the receiver operating characteristics curve analysis, and their areas under the curve (AUC) were obtained, respectively.

Updated Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt2)58 was used for functional prediction in Kyoto Encyclopedia of Genes and Genomes (KEGG). The significant P value in KEGG was then adjusted by false discovery rate (FDR). Spearman rank-correlation analysis was applied to explore the relationship between clinical features and specific microbiota taxa in ET. The ridge regression analysis was then performed to confirm the correlation effect, adjusting for sex, age, BMI, smoking, alcohol drinking, coffee drinking, tea drinking, and diabetes. P < 0.05 was considered as statistically significant.